Cargando…

Use of Genetically Modified Mesenchymal Stem Cells to Treat Neurodegenerative Diseases

The transplantation of mesenchymal stem cells (MSCs) for treating neurodegenerative disorders has received growing attention recently because these cells are readily available, easily expanded in culture, and when transplanted, survive for relatively long periods of time. Given that such transplants...

Descripción completa

Detalles Bibliográficos
Autores principales: Wyse, Robert D., Dunbar, Gary L., Rossignol, Julien
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Molecular Diversity Preservation International (MDPI) 2014
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3958818/
https://www.ncbi.nlm.nih.gov/pubmed/24463293
http://dx.doi.org/10.3390/ijms15021719
_version_ 1782307948506120192
author Wyse, Robert D.
Dunbar, Gary L.
Rossignol, Julien
author_facet Wyse, Robert D.
Dunbar, Gary L.
Rossignol, Julien
author_sort Wyse, Robert D.
collection PubMed
description The transplantation of mesenchymal stem cells (MSCs) for treating neurodegenerative disorders has received growing attention recently because these cells are readily available, easily expanded in culture, and when transplanted, survive for relatively long periods of time. Given that such transplants have been shown to be safe in a variety of applications, in addition to recent findings that MSCs have useful immunomodulatory and chemotactic properties, the use of these cells as vehicles for delivering or producing beneficial proteins for therapeutic purposes has been the focus of several labs. In our lab, the use of genetic modified MSCs to release neurotrophic factors for the treatment of neurodegenerative diseases is of particular interest. Specifically, glial cell-derived neurotrophic factor (GDNF), nerve growth factor (NGF), and brain derived neurotrophic factor (BDNF) have been recognized as therapeutic trophic factors for Parkinson’s, Alzheimer’s and Huntington’s diseases, respectively. The aim of this literature review is to provide insights into: (1) the inherent properties of MSCs as a platform for neurotrophic factor delivery; (2) the molecular tools available for genetic manipulation of MSCs; (3) the rationale for utilizing various neurotrophic factors for particular neurodegenerative diseases; and (4) the clinical challenges of utilizing genetically modified MSCs.
format Online
Article
Text
id pubmed-3958818
institution National Center for Biotechnology Information
language English
publishDate 2014
publisher Molecular Diversity Preservation International (MDPI)
record_format MEDLINE/PubMed
spelling pubmed-39588182014-03-20 Use of Genetically Modified Mesenchymal Stem Cells to Treat Neurodegenerative Diseases Wyse, Robert D. Dunbar, Gary L. Rossignol, Julien Int J Mol Sci Review The transplantation of mesenchymal stem cells (MSCs) for treating neurodegenerative disorders has received growing attention recently because these cells are readily available, easily expanded in culture, and when transplanted, survive for relatively long periods of time. Given that such transplants have been shown to be safe in a variety of applications, in addition to recent findings that MSCs have useful immunomodulatory and chemotactic properties, the use of these cells as vehicles for delivering or producing beneficial proteins for therapeutic purposes has been the focus of several labs. In our lab, the use of genetic modified MSCs to release neurotrophic factors for the treatment of neurodegenerative diseases is of particular interest. Specifically, glial cell-derived neurotrophic factor (GDNF), nerve growth factor (NGF), and brain derived neurotrophic factor (BDNF) have been recognized as therapeutic trophic factors for Parkinson’s, Alzheimer’s and Huntington’s diseases, respectively. The aim of this literature review is to provide insights into: (1) the inherent properties of MSCs as a platform for neurotrophic factor delivery; (2) the molecular tools available for genetic manipulation of MSCs; (3) the rationale for utilizing various neurotrophic factors for particular neurodegenerative diseases; and (4) the clinical challenges of utilizing genetically modified MSCs. Molecular Diversity Preservation International (MDPI) 2014-01-23 /pmc/articles/PMC3958818/ /pubmed/24463293 http://dx.doi.org/10.3390/ijms15021719 Text en © 2014 by the authors; licensee MDPI, Basel, Switzerland http://creativecommons.org/licenses/by/3.0/ This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
spellingShingle Review
Wyse, Robert D.
Dunbar, Gary L.
Rossignol, Julien
Use of Genetically Modified Mesenchymal Stem Cells to Treat Neurodegenerative Diseases
title Use of Genetically Modified Mesenchymal Stem Cells to Treat Neurodegenerative Diseases
title_full Use of Genetically Modified Mesenchymal Stem Cells to Treat Neurodegenerative Diseases
title_fullStr Use of Genetically Modified Mesenchymal Stem Cells to Treat Neurodegenerative Diseases
title_full_unstemmed Use of Genetically Modified Mesenchymal Stem Cells to Treat Neurodegenerative Diseases
title_short Use of Genetically Modified Mesenchymal Stem Cells to Treat Neurodegenerative Diseases
title_sort use of genetically modified mesenchymal stem cells to treat neurodegenerative diseases
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3958818/
https://www.ncbi.nlm.nih.gov/pubmed/24463293
http://dx.doi.org/10.3390/ijms15021719
work_keys_str_mv AT wyserobertd useofgeneticallymodifiedmesenchymalstemcellstotreatneurodegenerativediseases
AT dunbargaryl useofgeneticallymodifiedmesenchymalstemcellstotreatneurodegenerativediseases
AT rossignoljulien useofgeneticallymodifiedmesenchymalstemcellstotreatneurodegenerativediseases